
    
      In Escalation phase: MEDI4736 and gefitinib in NSCLC subjects In Expansion phase: Subjects
      with EGFR mutation positive locally advanced or metastatic NSCLC will be enrolled in
      expansion arms. Initiation of expansion arms with the recommended dose of MEDI4736 in
      combination with gefitinib will be based on an adequate safety and tolerability profile of
      the combination from the escalation phase.
    
  